Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.97 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.53 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Histidine SCHEMBL28977989 | 1.00 | CYP3A4 (0.97) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL28211929 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL2782316 | 0.98 | CYP3A4 (0.93) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL388560 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL3260 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL137600 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL28071764 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL30852263 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| D-Histidine SCHEMBL288043 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 | |
| Histidine SCHEMBL19974306 | 0.98 | CYP3A4 (1.00) | CYP3A4SLC7A5CPB2ALDH1A1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116615180-B | Hydroxyapatite composition for the treatment and/or prevention of viral infections | 库特沃夫博士有限及两合公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4588522-B1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | DR KURT WOLFF GMBH & CO KG (DE) | 2026-01-21 | — | — | EP | claimed |
| US-20260000707-A1 | Tablet with improved stability | NOBELPHARMA CO., LTD. (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250288653-A1 | ARTIFICIAL BLOOD SUBSTITUTES | CHANG THOMAS MING SWI (CA) | 2025-09-18 | — | — | US | claimed |
| EP-4588522-A2 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | Dr. Kurt Wolff GmbH & Co. KG (DE) | 2025-07-23 | — | — | EP | claimed |
| EP-4304738-B1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | DR KURT WOLFF GMBH & CO KG (DE) | 2025-06-18 | — | — | EP | claimed |
| EP-3973966-B1 | HYDROXYAPATITE COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A VIRUS INFECTION | DR KURT WOLFF GMBH & CO KG (DE) | 2025-02-26 | — | — | EP | claimed |
| US-20240148838-A1 | Composition for Treatment and/or Prevention of a Corona Virus Infection | DR. KURT WOLFF GMBH & CO. KG (DE) | 2024-05-09 | — | — | US | claimed |
| EP-3359138-B1 | DIETARY SUPPLEMENTATION TO ACHIEVE OXY-REDOX HOMEOSTASIS AND EPIGENETIC STABILITY | PARTHENOGEN SAGL (CH) | 2024-04-24 | — | — | EP | claimed |
| EP-4056234-B1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A CORONA VIRUS INFECTION | DR KURT WOLFF GMBH & CO KG (DE) | 2024-04-17 | — | — | EP | claimed |
| EP-1663141-B1 | AQUEOUS PHARMACEUTICAL SOLUTION CONTAINING OXYMETAZOLINE AND/OR XYLOMETAZOLINE | MERCK PATENT GMBH (DE) | 2007-03-21 | — | — | EP | claimed |
| US-20060222718-A1 | Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline | MERCK PATENT GMBH (DE) | 2006-10-05 | — | — | US | claimed |
| CN-1832726-A | Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline | MERCK PATENT GMBH (DE) | 2006-09-13 | — | — | CN | claimed |
| WO-2006083980-A1 | AN EMULSION COMPOSITION FOR WET WIPES CONTAINING A NON-IRRITATING SKIN HEALTH BENEFIT INGREDIENT AND THE PROCESS FOR MAKING SAID WET-WIPES | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060171971-A1 | Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making | THE PROCTER & GAMBLE COMPANY | 2006-08-03 | — | — | US | claimed |
| US-20040105894-A1 | Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions | GUPTA SHYAM K (US) | 2004-06-03 | — | — | US | claimed |
| EP-0245669-B1 | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs | FLOERSHEIM GEORG L (CH) | 1993-12-01 | — | — | EP | claimed |
| US-5234698-A | Increases amount of prostatic antibacterial factor | FAHIM MOSTAFA S (US) | 1993-08-10 | — | — | US | claimed |
| US-5071658-A | Increase antibacterial factor and inhibits growth; antiandrogen agent | FAHIM MOSTAFA S (US) | 1991-12-10 | — | — | US | claimed |
| US-4946688-A | ANTIGROWTH AGENTS | FAHIM MOSTAFA S (US) | 1990-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000707-A1 | Tablet with improved stability | GYS2, SORD, TREH | CYP3A4 2663/4885SLC7A5 257/4885CPB2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.